Jaguar animal health announces commercial availability of plant-based canalevia-ca1 (crofelemer) prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs

Canalevia®-ca1 is the first and only treatment for cid in dogs to receive any type of approval from fda san francisco, ca / accesswire / april 27, 2022 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that canalevia-ca1 (crofelemer delayed-release tablets), the company's prescription drug product for the treatment of chemotherapy-induced diarrhea (cid) in dogs, is now available from multiple leading veterinary distributors in the u.s. canalevia-ca1 received conditional approval from the fda on december 21, 2021. "we are very excited that canalevia-ca1 is now available to veterinarians across the country," said chip whitlow, sales & marketing director of the company's animal health commercial portfolio.
JAGX Ratings Summary
JAGX Quant Ranking